2013年8月20日訊 /生物谷BIOON/ --強(qiáng)生（JNJ）8月19日宣布，已完成對(duì)Aragon制藥的收購(gòu)。該公司是一家私營(yíng)藥品研發(fā)公司，業(yè)務(wù)主要集中在激素誘發(fā)的癌癥領(lǐng)域。

此次收購(gòu)，囊括了Aragon制藥雄激素受體拮抗劑項(xiàng)目，包括前列腺癌主導(dǎo)候選藥物ARN-509，該項(xiàng)目的開(kāi)發(fā)將由強(qiáng)生旗下楊森（Jassen）研發(fā)單元接管。

ARN-509是第二代雄激素受體信號(hào)抑制劑，目前正處于II期臨床開(kāi)發(fā)，如果獲批，將能夠滿足更廣泛的前列腺癌患者的需求。

此次收購(gòu)耗資10億美元，包括6.5億預(yù)付款項(xiàng)，及3.5億美元的履約款。（生物谷Bioon.com）

英文原文：Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.

Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline

NEW BRUNSWICK, N.J., Aug. 19, 2013 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced it has successfully completed its acquisition of Aragon Pharmaceuticals, Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.  Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development, LLC.

"The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound," said Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology. "It builds on our existing leadership position with ZYTIGA? (abiraterone acetate), and, if approved, we are hopeful ARN-509 will allow us to meet the needs of an even broader range of prostate cancer patients."

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.